SCHEMBL5654727

SCHEMBL5654727

COc1ccccc1NC(=O)OCCCN1CCN(c2ccccc2Cl)CC1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 2/20 0.62
ADRA1A P35348 2/20 0.62
ADRA1B P35368 2/20 0.62
CACNA1G O43497 2/20 0.56
HTR1A P08908 4/20 0.55
HTR7 P34969 4/20 0.55
DRD2 P14416 2/20 0.55
DRD4 P21917 1/20 0.55
DRD3 P35462 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.54
NPSR1 Q6W5P4 2/20 0.54
MEN1 O00255 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
KMT2A Q03164 1/20 0.53
ADORA2B P29275 1/20 0.53
HTR4 Q13639 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5657060 0.94 ADORA2B (0.60) ADRA1DADRA1AADRA1BCACNA1GL3MBTL1
SCHEMBL5655841 0.93 ADRA1A (0.71) ADRA1DADRA1AADRA1BHTR1AHTR7
SCHEMBL5655907 0.90 ADRA1D (0.53) ADRA1DADRA1AADRA1BCACNA1GHTR1A
SCHEMBL5655927 0.90 ADRA1A (0.62) ADRA1DADRA1AADRA1BHTR1AHTR7
SCHEMBL5655966 0.89 NPSR1 (0.69) ADRA1DADRA1AADRA1BHTR1AHTR7
SCHEMBL5655987 0.87 NPSR1 (0.69) ADRA1DADRA1AADRA1BCACNA1GHTR1A
SCHEMBL5657864 0.86 L3MBTL1 (0.59) ADRA1DADRA1AADRA1BHTR1ADRD3
SCHEMBL5656389 0.86 ADRA1D (0.65) ADRA1DADRA1AADRA1BHTR1AHTR7
SCHEMBL5654887 0.86 ADRA1A (0.66) ADRA1DADRA1AADRA1BHTR1AHTR7
SCHEMBL9559709 0.85 DRD2 (0.55) ADRA1ACACNA1GHTR1AHTR7DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-7238693-B2 Aryl carbamate derivatives, preparation and use thereof CEREP (FR) 2007-07-03 US disclosed
US-20040058933-A1 Aryl carbamate derivatives, preperation and use thereof CEREP (FR) 2004-03-25 US disclosed
EP-1362041-A1 ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF Cerep (FR) 2003-11-19 EP disclosed
WO-2002068399-A1 ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF CEREP (FR) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058933-A1 Aryl carbamate derivatives, preperation and use thereof HTR4, HTR5A, HTR3C ADRA1D 265/4885ADRA1A 294/4885ADRA1B 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.